Eurobio Scientific FY26 H1 net income more than doubles to €4.7 million; revenue rises 4.5% to €84.5 million
Bitget2026/09/24 15:40- Eurobio Scientific first-half revenue rose 4.5% to €84.5 million, while operating income climbed 45% to €8.5 million.
- Net income more than doubled to €4.7 million; EBITDA increased 20% to €15.8 million.
- Gross margin rate edged up 0.2 percentage points to 47.5%, and operating expenses fell to 35.1% of revenue from 37.2%.
- Free cash flow totaled €4 million, and net debt stood at €147.4 million, including the EB Development shareholder loan.
- CareDx’s Lab Solutions acquisition closed June 30, and EB Development proposed a tender offer at €25.30 per share.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Besent “Extinguishes Fire”: Rising US Treasury yields are a global phenomenon, dismisses concerns over AI bubble
U.S. Treasury Secretary Janet Yellen defended the rise in U.S. Treasury yields, stating that this increase is a global phenomenon rather than unique to the United States, and does not warrant excessive concern. She partially attributed inflationary pressures to higher oil prices caused by the Iran conflict, and expects the energy shock to subside as hostilities ease. Yellen refuted the notion of an AI bubble, arguing that investments by major tech companies are grounded in solid business logic.
Crypto prices
More
